Pseudomonas cepacia: biology, mechanisms of virulence, epidemiology.

Pseudomonas cepacia, originally described as a plant pathogen, has emerged as an important cause of infection in altered hosts, particularly in the hospital setting. This organism's ability to survive and proliferate in a variety of solutions, medications, and even disinfectants and antiseptics has resulted in numerous clusters of common-source nosocomial infections. Many patients exposed to P. cepacia are merely colonized, but serious infections, including surgical and burn wound infections, bacteremia, meningitis, pneumonia, peritonitis, and urinary tract infections, are not rare. The virulence properties of this pathogen remain poorly characterized. Recently, P. cepacia has been reported in some cystic fibrosis centers as an increasingly frequent pulmonary pathogen. This trend has caused considerable concern because of reports of occasional cases of fulminant necrotizing pneumonia and bacteremia. Conversely, many patients with CF who become colonized with this organism have no ill effects. The epidemiology of P. cepacia in the CF population is unclear, but some patients probably acquire the organism from colonized siblings with CF. Circumstantial evidence suggests that the organism may also be acquired in the hospital. Treatment of infections is exceedingly difficult, particularly in patients with CF, because P. cepacia is resistant to a broad range of antibiotics.

[1]  A. Spock,et al.  Bacteremia in Patients with Cystic Fibrosis , 1980, Clinical pediatrics.

[2]  M. Corey,et al.  Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. , 1984, The Journal of pediatrics.

[3]  Rosenstein Bj,et al.  Pneumonia and septicemia due to Pseudomonas cepacia in a patient with cystic fibrosis. , 1980 .

[4]  D. Dearborn,et al.  In vitro inhibition of lymphocyte proliferation by Pseudomonas aeruginosa phenazine pigments , 1983, Infection and immunity.

[5]  R. Baltimore,et al.  Occurrence of nonfermentative gram-negative rods other than Pseudomonas aeruginosa in the respiratory tract of children with cystic fibrosis. , 1982, Helvetica paediatrica acta.

[6]  J. Govan,et al.  Typing of Pseudomonas cepacia by bacteriocin susceptibility and production , 1985, Journal of clinical microbiology.

[7]  H. Greenlee,et al.  Pseudomonas cepacia strains isolated from water reservoirs of unheated nebulizers , 1976, Journal of clinical microbiology.

[8]  N. Palleroni,et al.  Pseudomonas cepacia sp. nov., nom. rev. , 1981 .

[9]  M. Favero,et al.  Morphological, biochemical, and growth characteristics of pseudomonas cepacia from distilled water. , 1973, Applied microbiology.

[10]  E. J. Benner,et al.  Necrotizing pneumonicitis due to the pseudomonad "eugonic oxidizer--group I". , 1968, The New England journal of medicine.

[11]  J. Pennington,et al.  Evaluation of a new polyvalent Pseudomonas vaccine in respiratory infections , 1979, Infection and immunity.

[12]  V. Jonsson Proposal of a new species Pseudomonas kingii1 , 1970 .

[13]  M. Thomassen,et al.  Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients. , 1985, Diagnostic microbiology and infectious disease.

[14]  G. Keusch,et al.  Association of Pseudomonas cepacia with chronic granulomatous disease , 1975, Journal of clinical microbiology.

[15]  S. Shapiro,et al.  Pseudobacteremia attributed to contamination of povidone-iodine with Pseudomonas cepacia. , 1981, Annals of internal medicine.

[16]  C. Nord,et al.  Synergistic Effect of Combinations of Sulfamethoxazole, Trimethoprim, and Colistin Against Pseudomonas maltophilia and Pseudomonas cepacia , 1974, Antimicrobial Agents and Chemotherapy.

[17]  D. Bassett,et al.  Foot lesions associated with Pseudomonas cepacia. , 1971, Lancet.

[18]  R. Kaslow,et al.  Aqueous quaternary ammonium antiseptics and disinfectants. Use and misuse. , 1976, JAMA.

[19]  P. Gilligan,et al.  Isolation medium for the recovery of Pseudomonas cepacia from respiratory secretions of patients with cystic fibrosis , 1985, Journal of clinical microbiology.

[20]  J. Pennington,et al.  Evaluation of Pseudomonas aeruginosa exotoxin A and elastase as virulence factors in acute lung infection , 1983, Infection and immunity.

[21]  A. Chakrabarty,et al.  Detoxification of 2,4,5-trichlorophenoxyacetic acid from contaminated soil by Pseudomonas cepacia , 1983, Applied and environmental microbiology.

[22]  R. Berkelman,et al.  Pseudomonas cepacia peritonitis associated with contamination of automatic peritoneal dialysis machines. , 1982, Annals of internal medicine.

[23]  G. Pulverer,et al.  4,9-Dihydroxyphenazine-1,6-dicarboxylic acid dimethylester and the 'missing link' in phenazine biosynthesis. , 1978, Journal of general microbiology.

[24]  J. Klinger,et al.  Comparison of cefpiramide (HR-810) and four anti-pseudomonal beta-lactam agents against pseudomonas isolates from children with cystic fibrosis. , 1985, The Journal of antimicrobial chemotherapy.

[25]  H. Monteil,et al.  O and H serotyping of Pseudomonas cepacia , 1983, Journal of clinical microbiology.

[26]  A. Vidaver,et al.  Bacteriocin, plasmid and pectolytic diversity in Pseudomonas cepacia of clinical and plant origin. , 1979, Journal of general microbiology.

[27]  D. Speller,et al.  Hospital infection by Pseudomonas cepacia. , 1971, Lancet.

[28]  D. Woods,et al.  Characterization of Pseudomonas cepacia isolates from patients with cystic fibrosis , 1984, Journal of clinical microbiology.

[29]  G. Gilardi Antimicrobial susceptibility as a diagnostic aid in the identification of nonfermenting gram-negative bacteria. , 1971, Applied microbiology.

[30]  R. Wenzel,et al.  Pseudomonas cepacia: implications and control of epidemic nosocomial colonization. , 1981, Reviews of infectious diseases.

[31]  J. Klinger,et al.  In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis , 1984, Antimicrobial Agents and Chemotherapy.

[32]  J. A. Bass,et al.  A rat model of chronic respiratory infection with Pseudomonas aeruginosa. , 2015, The American review of respiratory disease.

[33]  R. Stern,et al.  Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant pseudomonas. , 1985, The American journal of medicine.

[34]  S. Mitsuhashi,et al.  Purification and properties of a new beta-lactamase from Pseudomonas cepacia , 1980, Antimicrobial Agents and Chemotherapy.

[35]  M. Corey,et al.  Sputum bacteriology in patients with cystic fibrosis in a Toronto hospital during 1970-1981. , 1984, The Journal of infectious diseases.

[36]  H. Heymann,et al.  Fourteen-year survival of Pseudomonas cepacia in a salts solution preserved with benzalkonium chloride , 1979, Applied and environmental microbiology.

[37]  R. Klein,et al.  Cervical osteomyelitis caused by Pseudomonas cepacia in an intravenous-drug abuser , 1985, Journal of clinical microbiology.

[38]  T. Lessie,et al.  Response of Pseudomonas cepacia to beta-Lactam antibiotics: utilization of penicillin G as the carbon source , 1979, Journal of bacteriology.

[39]  H. Shwachman,et al.  STUDIES IN CYSTIC FIBROSIS A Report on Sixty-Five Patients over 17 Years of Age , 1965 .

[40]  C. Darby Treating Pseudomonas cepacia meningitis with trimethoprim-sulfamethoxazole. , 1976, American journal of diseases of children.

[41]  V. M. Young,et al.  In Vitro Susceptibility of Pseudomonas cepacia and Pseudomonas maltophilia to Trimethoprim and Trimethoprim-Sulfamethoxazole , 1975, Antimicrobial Agents and Chemotherapy.

[42]  M. Miller,et al.  Recurrent pneumonitis due to Pseudomonas cepacia. An unexpected phagocyte dysfunction. , 1975, The Western journal of medicine.

[43]  J. Rahal,et al.  Subacute and acute endocarditis due to Pseudomonas cepacia in heroin addicts. , 1975, The American journal of medicine.

[44]  W. Schaffner,et al.  Contaminated aqueous benzalkonium chloride. An unnecessary hospital infection hazard. , 1976, JAMA.

[45]  B. J. Wu,et al.  Selective medium for Pseudomonas cepacia containing 9-chloro-9-(4-diethylaminophenyl)-10-phenylacridan and polymyxin B sulfate , 1984, Applied and environmental microbiology.

[46]  P. Gilligan,et al.  Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. , 1985, The Journal of pediatrics.

[47]  E. Yabuuchi,et al.  [Serological classification of Pseudomonas cepacia]. , 1984, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.

[48]  P. Vos,et al.  Ribosomal ribonucleic acid cistron similarities of phytopathogenic Pseudomonas species , 1985 .

[49]  M. Doudoroff,et al.  Nucleic Acid Homologies in the Genus Pseudomonas , 1973 .

[50]  H. Levison,et al.  Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. , 1985, Pediatric infectious disease.

[51]  W. H. Burkholder Sour skin, a bacterial rot of Onion bulbs. , 1950 .

[52]  M. Nahata,et al.  Bacterial contamination of aerosol solutions used to treat cystic fibrosis. , 1982, American journal of hospital pharmacy.

[53]  D. Grant,et al.  Pseudomonas cepacia as contaminant and infective agent. , 1983, The Journal of hospital infection.

[54]  M D Reed,et al.  Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. , 1983, The Journal of antimicrobial chemotherapy.

[55]  J. Klinger,et al.  In-vitro activity of ciprofioxacin and other antibacterial agents against Pseudonwnas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients , 1985 .

[56]  J. Sanford,et al.  Bacterial contamination of aerosols. , 1973, Archives of internal medicine.

[57]  J. Klinger,et al.  PSEUDOMONAS CEPACIA BACTEREMIA IN CYSTIC FIBROSIS , 1984, Pediatric Research.

[58]  M. Corey,et al.  Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. , 1982, The Journal of pediatrics.

[59]  O. Sieber,et al.  PSEUDOMONAS CEPACIA PNEUMONIA IN A CHILD WITH CHRONIC GRANULOMATOUS DISEASE AND SELECTIVE IgA DEFICIENCY , 1976, Acta paediatrica Scandinavica.

[60]  H. Levison,et al.  Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis , 1983, Pediatric infectious disease.

[61]  A. Steere,et al.  Pseudomonas species bacteremia caused by contaminated normal human serum albumin. , 1977, The Journal of infectious diseases.

[62]  H. Levison,et al.  Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. , 1983, The Journal of antimicrobial chemotherapy.

[63]  J. Richards,et al.  Pseudomonas cepacia resistance to antibacterials. , 1979, Journal of pharmaceutical sciences.

[64]  R. Stern,et al.  Imipenem/cilastatin in acute pulmonary exacerbations of cystic fibrosis. , 1985, Reviews of infectious diseases.